View source for Sativex

{{TreatmentInfo
|drug_name=Sativex (Nabiximols)
|FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
|used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
|clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma
|common_side_effects=Fatigue, dizziness, nausea, mouth irritation
|OS_with=The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
|PFS_with=Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
|usefulness_rating=4
|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
|category=Investigational Drugs
|links=
}}